Search

Study Participation

     We are always looking for interested volunteers for our research studies.  The amazing breakthroughs in scientific research are due to the wonderful families and individuals who take part in these studies. We could not do this without YOU!

     If you are interested, please take a look at the table below for the current studies that are ongoing on the Indiana University School of Medicine Campus in Indianapolis.  You may also check out a free, national recruitment registry called ResearchMatch funded in part by the National Institutes of Health (NIH) that matches volunteers and researchers working in any number of diseases/studies. For Alzheimer disease and dementia research studies specifically, check out the Alzheimer's Prevention Registry and the Alzheimer's Association's TrialMatch for additional participation opportunties. Also, download this pdf participating-in-alzheimers-research.pdf for general information on Alzheimer disease clinical trials.

Who is needed?

For which study?

Length of study?

Please contact…

Participants need to: 

  • Have a first degree relative with Alzheimer disease caused by a known mutation. 
  • Be at least 18 years of age. 
  • Speak and read English. 
  • Have someone who knows them well and be willing to answer questions about their memory and thinking.
Dominantly Inherited Alzheimer Network (DIAN)

Longitudinally, visiting every 1-3 years, as long as the person is willing. 

Visits include: neurological exam, cognitive evaluation, PET and MRI imaging, informant interview, blood draw and spinal tap.

Compensation: travel, meals, accommodation, and completion of some procedures.

 

Melissa Wesson

317-278-9545

mkwesson@iu.edu

or

Christina Brown

317-963-7426

chbrown@iupui.edu

To participate, volunteers must have a diagnosis of one of the following:

• Probable Alzheimer Disease

• Mild Cognitive Impairment

• Lewy Body Disease

• Frontotemporal Dementia

• Mixed Dementia

• Vascular Dementia

• Parkinson Dementia

This Research Registry/database is used to capture data for self-referred volunteers and established clinic patients who have interest in participating in clinical research and drug studies now and in the future.

Information regarding research projects will be disclosed prior to enrollment in specific research studies.

Length varies by individual study.

Christina Brown

317-963-7426

chbrown@iupui.edu

Families with 3 or more living siblings diagnosed with probable AD.

 

The Genetics of Late Onset Alzheimer’s Disease (LOAD) Study

Longitudinal; over a lifetime or as long as person is willing.

Visits include: neurological exam, cognitive evaluation, informant interview and provide a blood sample for DNA at first visit.

National Cell Repository for AD

1-800-526-2839

alzstudy@iupui.edu

  • People with mild to moderate memory difficulties.
  • 60 years of age or older.
  • Right-handed.
  • Completed at least 8th grade.
  • Be in good general health
  • Have someone who knows them well and can answer questions about their memory.

Indiana Memory and Aging Study (IMAS).

Study includes brain scans, blood draw, eye exam and cognitive testing.

  • Longitudinal; over a lifetime or as long as person is willing.

  • Assessments are 18 months apart.

  • Each visit is 10.5 hours and will be scheduled over 2 days.

Compensation:

  • $175 for each visit
  • $50 for optional lumbar puncture.
  • Parking is validated.

Eileen Tallman

317-278-3121

etallman@iupui.edu

  • Familes with two or more living members with AD or symptoms of serious memory loss.

  • Eager to involve new families from all locations.

The National Cell Repository for Alzheimer's Disease (NCRAD)

  • Longitudinal; over a lifetime or as long as person is willing. 

  • Visits are done by telephone or mail.

National Cell Repository for AD

1-800-526-2839

alzstudy@iupui.edu


  • Be 55-90 years of age
  • MMSE score between 20-26.
  • Have Mild Alzheimer Disease.
  • Have amyloid pathology present at screening.
  • Be stable 12 weeks prior to screen if using AChEIs. 

Lilly: H8A-MC-LZAX.

A research study to assess the effects of passive immunization on the progression of mild AD; Solanezumab (LY2062430) versus placebo.

  • Approximately 25 visits within 18 months.

  • Visits are 3-6 hours long.

  • You will receive monthly IV infusion if eligible for study. 

Compensation:

  • $75 for 5 visits
  • $50 for all other visits
   

Lyla Christner, LPN

317-963-7411

lychrist@iupui.edu


  • 65-85years of age.
  • MMSE score of 27-30 if more than high school education
  • MMSE 25-30 if only high school education.
  • Amyloid pathology present at screening.
  • Be living independently.
  • Have a study partner accompany.

A4 LZAZ ADC-040 Study

An anti-amyloid treatment in asymptomatic Alzheimer's Disease. Study assesses the effects of Solanezumab (LY2062430) versus placebo in slowing cognitive decline in preclinical AD.

  • Receive monthly IV infustion of drug or placebo.
  • Visits are 3-6 hours.
  • Approximately 164 weeks.
  • Clinic visit every 4 weeks.

Compensation:

  • $50 for each completed clinic visit.
  • $75 for optional lumbar puncture at visit #5.
  • $125 for final visit of optional lumbar puncture.
  • Complimentary parking.

Nancy McClaskey

317-963-7429

nmcclask@iupui.edu

or

Christina Brown

317-963-7426

chbrown@iupui.edu

 

  • Be 50-90 years old.
  • Have mild AD (MMSE 20-26).
  • Have a study partner to accompany you. 

Roche WN28745 Study.

 A research study to assess the effect of Gantenerumab injections. 

  • Receive monthy injections of drug or placebo.
  • Visits are 3-6 hours long.

  • Compensation: $50 per visit

    .

Nancy McClaskey, RN CCRP

317-963-7429

nmcclask@iupui.edu

 


 

  • 66-85 years of age.

  • Up to 90 years of age with medical monitor approval.

  • MMSE 14-26.

  • AChEIs, Namenda if stable 12 weeks prior to screen.

 

Nourish

Placebo-controlled study of effects of daily administration of AC-1204 in participants with mild to moderate AD. 

  • 26 weeks with optional 26 week open label extension.

 Compensation:

  • 5 clinic visits - $75 each
  • Phone interviews - $25 each.

Scott Herring

317-963-7418

sherring@iupui.edu

or

Christina Brown

317-963-7426

chbrown@iupui.edu

  • 55-85 years of age.
  • MMSE score of 20 or greater.

SNIFF

Study of Nasal Insulin to Fight Forgetfulness

A multi-center, double blind, placebo-controlled phase II/III study to evaluate impact of nasal inhaled insulin in participants with mild and early AD. 

  • Blind study for 12 months.
  • Followed by 6 months open label (all participants receive insulin).

Compensation:

  • $75 for each completed lumbar puncture.
  • Complimentary parking.

Scott Herring, RN

317-963-7418

sherring@iupui.edu 

  • Be 50-90 years of age.
  • MMSE score of 24-30 or 20-26. 
  • Have amyloid pathology present at screening.
  • Have a study partner to accompany you.

Biogen 221AD103 Study

 A research study to assess the effect of BllB037 versus placebo in subjects with prodromal or mild AD.

  • Receive monthly IV infustion of drug or placebo.
  • Visits are 3-6 hours.
  • Approximately 27 visits to center with caregiver.
  • Possibility of a long term extension to the study if qualified.

Compensation:

  • $85 per visit.

Nancy McClaskey, RN CCRP

317-963-7429

nmcclask@iupui.edu

 

Participants need to:

  • Be 50-90 years of age
  • AChEIs and/or memantine allowed if stable dose for at least 12 weeks prior to baseline
  • Have a BMI<35 at screening
  • Have a MMSE 22+

Eisai

 A placebo-controlled, double-blind, parallel-group, dose regimen-finding study to evaluate safety, tolerability, and efficacy of BAN2401 in subjects with early AD, defined as mild cognitive impairment due to AD.

  • Up to 41 months
  • Average visit 3-6 hours

Compensation:

  • Varies from $50 to $100 visit; up to $2600 maximum.

Lyla Christner

317-963-7411

lychrist@iupui.edu

or

Christina Brown

317-963-7426

chbrown@iupui.edu

  • Be at least 50 years of age.
  • Diagnosed with probable Alzheimer disease with MMSE 12-22.
  • Have a reliable caregiver who can come to study visits.
  • Taking ONLY donepezil/Aricept 10mg/day for 4 months
  • Not taking Namenda.

Lundbeck study.

This study assesses the benefits of adding study medication to patients already taking donepezil/Aricept.

  • 28  weeks with option of open label extension (getting study drug) of another 28-32 weeks.

Scott Herring, RN

317-963-7418

sherring@iupui.edu 

  • Be 50-79 years of age.
  • Diagnosed with moderate Alzheimer disease with MMSE score 10-20.
  • Be taking ONLY donepezil/Aricept 10mg/day for 3 months.
  • Not taking Namenda.
  • Have reliable caregiver who can come to study visits.

Chase Study.

This study assesses effects of higher doses of donepezil/Aricept combined with Vesicare/solifenacin.

  • Study length could be as long as 190 days pending tolerability.

Scott Herring, RN

317-963-7418

sherring@iupui.edu 

355 W. 16th Street, Suite 4100 | Indianapolis, IN 46202 | Phone: 317-963-5500 | Fax: 317-963-7547